peoplePerson
Joaquín Arribas
Cancer biologist who characterised truncated HER2 (p95HER2) and develops p95HER2-targeted T-cell engagers.
Joaquín Arribas led the Growth Factors group at VHIO for two decades, discovering how p95HER2 confers resistance to trastuzumab and developing T-cell bispecifics against it; he now directs the Hospital del Mar Research Institute.
Role
Director, Hospital del Mar Research Institute; ICREA Professor; formerly VHIO
Institution
Specialisms
HER2 biologyResistance to anti-HER2 therapyT-cell bispecifics
Profiles
Pages like this
not linked directly; found by shared links- ProductTrastuzumab duocarmazine
Shares HER2, HER2-positive breast cancer.
- TrialDESTINY-Breast09
Shares Vall d'Hebron University Hospital / VHIO, HER2-positive breast cancer.
- PersonFei Ma
Shares HER2, HER2-positive breast cancer.
- PersonNancy U. Lin
Shares HER2, HER2-positive breast cancer.
- IdeaUse the brain's own transport door to carry antibody drugs across
Shares T-cell engagers (bispecific), HER2, HER2-positive breast cancer.
- ProductTrastuzumab brengitecan
Shares HER2, HER2-positive breast cancer.
- ProductTrastuzumab biosimilars
Shares HER2, HER2-positive breast cancer.
- InstitutionInstituto Alexander Fleming
Shares HER2, HER2-positive breast cancer.